Novanta (NOVT)
NASDAQ:NOVT
Want to see NOVT full AI Analyst Report?
Top Page
Novanta
(NASDAQ:NOVT)
Select Model
Select Model
Rating:70Outperform
Price Target:
$181.00
▲(40.47% Upside)
Action:Upgraded
Date:06/10/26
Overall score is driven by solid financial footing (notably improved leverage) and strong technical momentum, supported by a constructive earnings outlook and bookings/new-product traction. These positives are tempered by a very expensive valuation and added execution/leverage risk from the large Riverpoint acquisition, alongside near-term margin pressure from tariffs and cost inflation.
Positive Factors
Improved Balance Sheet
Material deleveraging and a net cash position strengthen Novanta's financial flexibility for the next several quarters. A stronger capital structure reduces refinancing and liquidity risk, supports disciplined M&A or capex, and provides buffer against cyclical end-market swings.
Negative Factors
Acquisition Leverage & Execution Risk
The Riverpoint acquisition meaningfully increases leverage near term, constraining financial flexibility and elevating refinancing and covenant risk. Integration/regulatory execution demands can divert management attention, heightening the chance synergies or cash flow benefits are delayed or reduced.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Material deleveraging and a net cash position strengthen Novanta's financial flexibility for the next several quarters. A stronger capital structure reduces refinancing and liquidity risk, supports disciplined M&A or capex, and provides buffer against cyclical end-market swings.
Read all positive factors
Novanta Key Performance Indicators (KPIs)
Any
Revenue by Geography
Data provided by:
The Fly
The FlyNovanta (NOVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.53B
Dividend YieldN/A
Average Volume (3M)542.21K
Price to Earnings (P/E)116.9
Beta (1Y)1.62
Revenue Growth5.59%
EPS Growth-28.67%
CountryUS
Employees3,000
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)1.40
Shares Outstanding35,611,860
10 Day Avg. Volume562,531
30 Day Avg. Volume542,213
Financial Highlights & Ratios
PEG Ratio-4.64
Price to Book (P/B)3.31
Price to Sales (P/S)4.44
P/FCF Ratio89.90
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue5.27
Enterprise Value/Gross Profit12.70
Enterprise Value/Ebitda35.35
Forecast
1Y Price Target
$180.00Price Target Upside39.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.56
Revenue Forecast (FY)$1.05B
Novanta Business Overview & Revenue Model
Company Description
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supp...
How the Company Makes Money
Novanta makes money primarily by selling engineered components and subsystems to OEM customers who incorporate them into their end products. Revenue is generated from (1) product sales of motion/precision technologies (e.g., motors, encoders, driv...
Novanta Earnings Call Summary
Earnings Call Date:May 11, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational momentum: robust bookings (+37%), improving organic growth trajectory, expanding profitability (adjusted EBITDA +14%, margin +70 bps), accelerating new product revenue (+~50%) and excellent cash generation (>200% cash conversion). These positives were tempered by near-term gross margin pressure from sudden tariff and freight cost increases, a modest $0.03 EPS headwind, and timing risk as repricing and manufacturing consolidation benefits are expected to materialize in the back half of the year. Management reaffirmed and tightened full-year guidance and outlined clear actions (surcharges, price increases, site consolidations) to restore margins, leaving the overall tone constructive.Positive Updates
Revenue Growth and Upgraded Guidance
Q1 reported revenue grew 10% year-over-year with 3% organic growth (an inflection versus the prior quarter). Management raised full-year GAAP revenue guidance to $1,040M–$1,055M (reported growth >7%, organic growth up to 6%) and expects Q2 organic growth of 6%–8%.
Negative Updates
Gross Margin Pressure from Tariffs and Cost Inflation
Adjusted gross margin was $118M (45.6%) in Q1, down ~60 basis points year-over-year (Automation segment margin down ~60 bps). Management cited higher freight, tariff increases and material costs as a timing-driven negative that outpaced the ability to surcharge and reprice orders.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Upgraded Guidance
Q1 reported revenue grew 10% year-over-year with 3% organic growth (an inflection versus the prior quarter). Management raised full-year GAAP revenue guidance to $1,040M–$1,055M (reported growth >7%, organic growth up to 6%) and expects Q2 organic growth of 6%–8%.
Read all positive updates
Company Guidance
Novanta's guidance for 2026 calls for Q2 GAAP revenue of $259–$264M (organic growth 6–8%, reported up to 10%), adjusted gross margin ~45.5–46%, adjusted EBITDA $58–$62M (≈23% margin, high‑teens YoY growth), diluted EPS $0.81–$0.86 (up 6–13% YoY), R&D+SG&A ~$74–$75M (~28–29% of sales), stock comp ~$10M, depreciation ≈$4M, interest ≈$2M, a non‑GAAP tax rate of 20–22% and ~41M diluted shares; for the full year they reaffirmed GAAP revenue of $1,040–$1,055M (reported growth >7%, organic up to 6%), adjusted EBITDA $245–$250M (11–13% YoY), adjusted EPS $3.50–$3.65 (6–11% YoY), a goal of mid‑single‑digit (or higher) organic growth, cash‑flow conversion ≥100% and a planned second‑half gross‑margin step‑up as price/surcharge actions and two regional site closures take effect (tariff‑refunds not assumed).Novanta Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
78
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00B | 980.60M | 949.25M | 881.66M | 860.90M | 706.79M |
| Gross Profit | 416.81M | 407.81M | 421.55M | 399.90M | 378.47M | 300.33M |
| EBITDA | 149.78M | 153.05M | 179.86M | 169.92M | 160.62M | 125.47M |
| Net Income | 53.72M | 53.83M | 64.09M | 72.88M | 74.05M | 50.33M |
Balance Sheet | ||||||
| Total Assets | 1.80B | 1.81B | 1.39B | 1.23B | 1.24B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 388.80M | 380.87M | 113.99M | 105.05M | 100.11M | 117.39M |
| Total Debt | 290.49M | 341.61M | 471.00M | 404.56M | 489.38M | 493.40M |
| Total Liabilities | 488.03M | 492.82M | 642.81M | 552.60M | 663.63M | 706.59M |
| Stockholders Equity | 1.31B | 1.31B | 745.70M | 673.46M | 577.59M | 521.29M |
Cash Flow | ||||||
| Free Cash Flow | 67.20M | 48.43M | 141.35M | 100.11M | 71.14M | 72.45M |
| Operating Cash Flow | 82.69M | 64.06M | 158.51M | 120.08M | 90.78M | 94.63M |
| Investing Cash Flow | -79.37M | -74.32M | -208.19M | -19.89M | -42.54M | -306.70M |
| Financing Cash Flow | 280.23M | 276.33M | 56.94M | -97.85M | -60.15M | 204.75M |
Novanta Technical Analysis
Neutral
128.85
Price Trends
145.59
Positive
137.96
Positive
126.94
Positive
Market Momentum
2.45
Positive
50.65
Neutral
22.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Neutral. The current price of 128.85 is below the 20-day moving average (MA) of 159.97, below the 50-day MA of 145.59, and above the 200-day MA of 126.94, indicating a neutral trend. The MACD of 2.45 indicates Positive momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 22.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NOVT.
Novanta Risk Analysis
Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Novanta Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $15.10B | 110.23 | 20.22% | ― | 15.59% | 491.65% | |
78 Outperform | $8.90B | 28.88 | 20.50% | 0.16% | 16.43% | 14.49% | |
71 Outperform | $8.03B | 42.81 | 12.83% | ― | 8.64% | 32.91% | |
70 Outperform | $5.53B | 116.87 | 5.08% | ― | 5.59% | -28.67% | |
62 Neutral | $3.67B | 24.11 | 16.74% | ― | 6.98% | 8.41% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | $7.36B | 152.17 | 1.72% | 1.43% | -3.37% | -59.55% |
* Technology Sector Average
NOVT
Novanta
155.30
34.74
28.82%
ESE
Esco Technologies
343.50
162.32
89.59%
OSIS
OSI Systems
222.78
7.83
3.64%
PLXS
Plexus
299.97
169.26
129.48%
ST
Sensata
50.63
22.75
81.57%
VICR
Vicor
331.37
287.30
651.92%
Novanta Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Novanta Announces $300 Million Private Share Placement
Neutral
Jun 9, 2026
On June 8, 2026, Novanta entered into a securities purchase agreement for a private placement of 2,142,857 common shares to institutional and other accredited investors at $140 per share, for expected gross proceeds of about $300 million. Assuming...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Novanta to Acquire Riverpoint Medical in Strategic Deal
Positive
Jun 9, 2026
On June 8, 2026, Novanta agreed to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, for $1.2 billion in upfront cash plus a $250 million milestone payment due by early 2027, with closing expected in the thi...
Business Operations and StrategyPrivate Placements and Financing
Novanta Expands Credit Facilities with New Term Loan
Positive
May 15, 2026
On May 15, 2026, Novanta Inc. and several of its subsidiaries amended their existing credit agreement to add $200 million in delayed draw term loan commitments, available for up to six months after that date and maturing on June 27, 2030. The loan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.